Neurocrine Adds Four Gene Therapies to Pipeline with Voyager Collaboration

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)

Published: 6 Feb-2019

DOI: 10.3833/pdr.v2019.i2.2402     ISSN: 1756-7874

Section: Research & Development



Expanding its pipeline of gene therapies for neurological disorders, Neurocrine Biosciences has partnered up with Voyager Therapeutics to develop and commercialise four of Voyager’s gene therapy programmes – VY-AADC for Parkinson’s disease (PD) and VY-FXN01 for Friedreich’s ataxia (FA) as well as rights to two programmes to be determined...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details